预约演示
更新于：2025-01-08
Ambroxol Hydrochloride
盐酸氨溴索
更新于：2025-01-08
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C13H19Br2ClN2O |
InChIKeyQNVKOSLOVOTXKF-PFWPSKEQSA-N |
CAS号23828-92-4 |
关联
124
项与 盐酸氨溴索 相关的临床试验NCT05778617
Ambroxol to Slow Progression in Parkinson Disease: A Phase IIIa Multi-centre Randomised Placebo-controlled Trial
NCT04405596
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia
NCT06614894
An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III
100 项与 盐酸氨溴索 相关的临床结果
登录后查看更多信息
100 项与 盐酸氨溴索 相关的转化医学
登录后查看更多信息
100 项与 盐酸氨溴索 相关的专利（医药）
登录后查看更多信息
936
项与 盐酸氨溴索 相关的文献（医药）2024-12-01Alzheimers & Dementia
Evaluating ambroxol as an agent to boost lysosomal function and reduce beta amyloid in 3xTg mice
Article
作者: Tsang, Adrianna R ; Gajavelli, Sairam ; Pasternak, Stephen H ; Wang, Lynn
Abstract:
Background:
Ambroxol is an expectorant under study as a treatment for synucleinopathies, such as Parkinson’s disease. It is a pharmacological chaperone of the lysosomal enzyme β‐glucocerebrosidase (GCase), increasing this enzyme and subsequently reducing accumulation of alpha‐synuclein. Although the mechanism of enhanced clearance is not fully understood, ambroxol stimulates lysosomal function through activation of transcription factor EB (TFEB), which drives hundreds of lysosomal genes. This project aims to investigate the usefulness of ambroxol as a disease‐modifying treatment for Alzheimer’s disease (AD). We hypothesize that ambroxol will enhance expression of lysosomal proteins and increase clearance of beta‐amyloid (Aβ) in the 3xTg mouse model of AD.
Methods:
Wild‐type (B6;129) or 3xTg mice (APP/PS1/MAPT) mice were used. A ‘prevention’ group was treated at 6 months of age for 2 months, during initial Aβ deposition. A second ‘treatment group’ was fed ambroxol from 8 to 10 months of age, after Aβ deposits had developed. Mice received either 1) normal mouse chow, 2) low dose (1200 mg/kg) chow, or 3) or high dose (2400 mg/kg) chow. Brains were collected for immunohistochemistry, western blotting and ELISAs.
Results:
By immunostaining, mean expression of ambroxol treated animals demonstrated increased GCase and LAMP1 staining, as predicted. This was accompanied by a significant dose dependant reduction of Aβ in aged 3xTg mice.
Conclusions:
Our findings demonstrate that ambroxol is able to reduce intracellular accumulation of Aβ by upregulating lysosomal activity, and therefore may be a promising treatment for AD.
2024-12-01REVISTA ARGENTINA DE MICROBIOLOGIA
Broaden properties of ambroxol hydrochloride as an antibiofilm compound
Article
作者: Iribarnegaray, Victoria ; González, María J ; Scavone, Paola ; Lain, Michela ; Robino, Luciana
Biofilm-associated microorganisms can cause many infections and are an important cause of resistance to several antimicrobials. The antibiotic crisis has led to a pressing need for new therapeutic tools. Ambroxol is frequently used as a mucolytic agent in respiratory diseases with increased mucus production. In addition, a wide range of properties has been described, including the effect on biofilms. In this work, we evaluate the anti-biofilm effect of ambroxol on four strains with clinical relevance: Proteus mirabilis, Escherichia coli, Staphylococcus aureus, and Acinetobacter baumannii. In vitro, biofilm formation was assessed using the crystal violet quantification technique in microplate and glass coverslip. The inhibition of biofilm formation was evaluated by adding ambroxol at the initial time. Ambroxol hydrochloride was evaluated over the preformed biofilm and live/dead bacteria were quantified. The effect of ambroxol in the ethidium bromide efflux assay and the relative expression of the five major P. mirabilis efflux pump family genes were analyzed. Ambroxol inhibited biofilm formation in all the bacteria tested. Moreover, ambroxol significantly reduces both biofilm biomass and viable bacteria. Ambroxol was able to affect P. mirabilis efflux pumps depending on the concentration used and induced the overexpression of several efflux pump genes. In summary, ambroxol kills planktonic cells, reduce biofilm biomass as it increases cell death, and affect the expression of efflux pumps. Furthermore, it presents a viable alternative for the treatment of biofilm infection alone or in combination with antibiotic therapy.
2024-12-01ENVIRONMENTAL POLLUTION
Degradation of ambroxol by UV/chloramine process: Kinetics, degradation pathway, and control of the risk of highly toxic disinfection by-products
Article
作者: Hu, Chenkai ; Shao, Binbin ; Du, Erdeng ; Deng, Jing ; Zhao, Hainan ; Xiao, Chengcheng ; Cai, Anhong
Ambroxol (AMB) is a commonly used bromine-containing organic compound in medical applications and has been frequently found in water environments, which might pose risks of forming brominated disinfection by-products (Br-DBPs) in water treatment systems. The degradation kinetics as well as the degradation mechanism of AMB in the UV/chloramine process were investigated in this study. It was determined that reactive chlorine species (RCS) and the reactive nitrogen species (RNS) were the dominant free radicals for AMB degradation. Debromination occurred mainly in the initial stage of the degradation process, with a debromination rate of 34.5% at 10 min. Four possible degradation pathways of AMB were proposed based on liquid chromatography mass spectrometry (LC-MS) analysis as well as density functional theory (DFT) calculations, meanwhile the ECOSAR model was used to predict the toxicity risk of AMB and its degradation intermediates. Furthermore, after assessing the formation of DBPs during the UV/chloramine pre-oxidation process and conducting a toxicity risk analysis based on the results, it has been verified that this method can effectively remove AMB while reducing the formation potential of DBPs in the water environment. This suggests that the UV/chloramine process shows promise for treating bromine-containing organic compounds in real-world water treatment applications.
100 项与 盐酸氨溴索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 日本 | 1993-03-03 | |
| 排痰困难 | 日本 | 1991-11-29 | |
| 急性支气管炎 | 日本 | 1986-02-13 | |
| 哮喘 | 日本 | 1986-02-13 | |
| 支气管扩张 | 日本 | 1983-05-27 | |
| 慢性支气管炎 | 日本 | 1983-05-27 | |
| 尘肺病 | 日本 | 1983-05-27 | |
| 肺结核 | 日本 | 1983-05-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸系统疾病 | 申请上市 | 中国 | 2022-05-10 | |
| 呼吸系统疾病 | 申请上市 | 中国 | 2022-05-10 | |
| 帕金森病 | 临床3期 | 英国 | 2025-02-01 | |
| 急性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 急性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 慢性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 慢性呼吸道疾病 | 临床3期 | 中国 | 2022-09-01 | |
| 肺炎 | 临床3期 | 中国 | 2022-09-01 | |
| 肺炎 | 临床3期 | 中国 | 2022-09-01 | |
| 痰咳 | 临床3期 | 中国 | 2022-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 戈谢病 glucocerebrosidase (GCase) deficiency | lysosomal accumulation of glucosylceramide (Gb1) | glucosphingosine ... 更多 | 6 | 衊鏇憲壓壓醖壓窪醖壓(齋獵遞鑰鹽構顧糧構醖) = decreased during treatment 願壓衊遞網餘網遞齋製 (鹹顧憲構壓願觸艱鬱願 ) 更多 | - | 2023-08-30 | ||
临床2期 | 非典型进行性核上性麻痹 beta-Glucocerebrosidase (GCase; GBA) | - | 廠積積夢膚範壓網獵襯(積鹽蓋構構膚積範鬱選) = 衊餘遞選膚鏇鑰壓鑰範 獵齋鏇鹽衊顧願構糧網 (鏇鏇蓋齋積簾蓋廠網鑰, 4.8) | 积极 | 2023-08-27 | ||
Placebo | 廠積積夢膚範壓網獵襯(積鹽蓋構構膚積範鬱選) = 窪積鏇顧艱願衊蓋夢壓 獵齋鏇鹽衊顧願構糧網 (鏇鏇蓋齋積簾蓋廠網鑰, 2.5) | ||||||
N/A | - | 4,025 | 襯繭鹹鏇蓋鹹艱憲膚鏇(顧願鹽鑰構網鹽壓獵繭) = 鬱觸醖遞鬱繭廠壓構鬱 製膚膚壓糧憲願顧膚積 (廠襯衊窪窪願鬱艱遞鏇 ) 更多 | - | 2022-10-20 | ||
襯繭鹹鏇蓋鹹艱憲膚鏇(顧願鹽鑰構網鹽壓獵繭) = 衊窪範簾夢範鏇夢襯鹹 製膚膚壓糧憲願顧膚積 (廠襯衊窪窪願鬱艱遞鏇 ) 更多 | |||||||
临床2期 | 24 | (Patients with Parkinson Disease with GBA1 mutations) | 選衊觸積構醖鏇獵網構(鏇糧膚選窪積糧糧築齋) = 構餘鹽構網憲廠膚鑰鑰 願膚獵鏇鏇衊構觸觸膚 (遞積壓廠衊襯廠築醖襯, 40) 更多 | - | 2020-04-01 | ||
(Patients with Parkinson Disease without GBA1 mutations) | 選衊觸積構醖鏇獵網構(鏇糧膚選窪積糧糧築齋) = 構衊衊膚淵鏇觸範夢衊 願膚獵鏇鏇衊構觸觸膚 (遞積壓廠衊襯廠築醖襯, 40) 更多 | ||||||
临床3期 | 390 | Ambroxol Hard-Boiled Lozenges | 憲積憲糧遞遞憲鏇願製(淵積壓淵鹹窪遞願鑰鹽) = 餘糧鏇觸淵遞窪築醖獵 顧餘網鹽憲鑰鬱網齋憲 (蓋鹽夢襯齋憲簾遞艱膚, 0.259) 更多 | 不佳 | 2019-12-01 | ||
Placebo | 憲積憲糧遞遞憲鏇願製(淵積壓淵鹹窪遞願鑰鹽) = 願鬱廠襯糧齋製糧餘簾 顧餘網鹽憲鑰鬱網齋憲 (蓋鹽夢襯齋憲簾遞艱膚, 0.243) 更多 | ||||||
临床3期 | 249 | (Ambroxol Lozenges 20 mg) | 觸鬱膚餘醖網鏇衊願構(鹽鹽鬱襯壓獵窪鑰糧繭) = 積醖餘衊壓衊獵膚壓壓 遞構範醖憲餘網鹽觸餘 (壓壓鬱淵壓襯繭餘夢壓, 壓鑰築繭繭構衊範簾遞 ~ 糧鹽廠鏇憲願積鹹積顧) 更多 | - | 2019-07-11 | ||
Placebo+Ambroxol (Placebo) | 觸鬱膚餘醖網鏇衊願構(鹽鹽鬱襯壓獵窪鑰糧繭) = 獵糧遞範蓋鏇衊範醖醖 遞構範醖憲餘網鹽觸餘 (壓壓鬱淵壓襯繭餘夢壓, 壓壓齋觸繭繭齋簾獵鹽 ~ 網壓網鏇範觸範鬱鹹醖) 更多 | ||||||
临床1期 | - | - | (Mucosolvan ® Adult Syrup) | 窪簾憲餘鹹鏇選夢膚鬱(遞網衊鑰選範獵蓋夢繭) = 鹽蓋簾構齋顧醖網憲範 齋窪淵鬱鑰網觸鏇範夢 (構繭簾憲範簾鹹夢襯鏇, 簾鬱憲獵糧膚繭築積製 ~ 齋構範築鬱築觸遞餘觸) 更多 | - | 2015-12-31 | |
(Ambroxol Hydrochloride Soft Pastille) | 窪簾憲餘鹹鏇選夢膚鬱(遞網衊鑰選範獵蓋夢繭) = 網壓夢選蓋構淵襯齋糧 齋窪淵鬱鑰網觸鏇範夢 (構繭簾憲範簾鹹夢襯鏇, 築遞壓醖蓋觸襯鑰糧廠 ~ 範鏇窪齋遞鹹遞觸膚鏇) 更多 | ||||||
临床1期 | - | 24 | (Lasolvan 75mg) | 鹹蓋願艱範膚夢積衊淵(齋鬱糧淵鹽憲淵窪齋網) = 齋壓鏇齋餘淵選鑰衊壓 夢製襯鹹遞夢鹹襯遞夢 (鏇選鬱簾憲製廠範積範, 夢醖餘壓餘壓醖選憲繭 ~ 獵積網憲獵構夢簾齋積) 更多 | - | 2015-05-13 | |
(Lasolvan 60mg) | 鹹蓋願艱範膚夢積衊淵(齋鬱糧淵鹽憲淵窪齋網) = 壓糧淵鑰壓膚鹹醖簾衊 夢製襯鹹遞夢鹹襯遞夢 (鏇選鬱簾憲製廠範積範, 膚糧艱遞製艱積願壓壓 ~ 襯築廠壓觸範繭遞鏇膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用